Souers; Andrew

Patent Applications and Registrations

Patent applications and USPTO patent grants for Souers; Andrew.The latest application filed is for "macrocyclic mcl-1 inhibitors and methods of use".

Company Profile

5.10.29

Souers; Andrew - Libertyville IL
Souers; Andrew - Evanston IL

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Macrocyclic Mcl-1 Inhibitors And Methods Of Use App 20220259226 - Braje; Wilfried ; et al.	2022-08-18
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20210403467 - Tao; Zhi-Fu ; et al.	2021-12-30
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20210346369 - WANG; Le ; et al.	2021-11-11
Macrocyclic Mcl-1 Inhibitors And Methods Of Use App 20210292339 - BRAJE; Wilfried ; et al.	2021-09-23
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20210228565 - Wang; Le ; et al.	2021-07-29
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20200345717 - WANG; Le ; et al.	2020-11-05
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20200331907 - Tao; Zhi-Fu ; et al.	2020-10-22
Macrocyclic Mcl-1 Inhibitors And Methods Of Use App 20200255451 - Kind Code	2020-08-13
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20200253954 - Kind Code	2020-08-13
Macrocyclic Mcl-1 Inhibitors And Methods Of Use App 20200239494 - BRAJE; Wilfried ; et al.	2020-07-30
Methods Of Treatment Using Selective Bcl-2 Inhibitors App 20200222413 - Elmore; Steven ; et al.	2020-07-16
Methods Of Treatment Using Selective Bcl-2 Inhibitors App 20180369250 - Elmore; Steven ; et al.	2018-12-27
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20180354952 - Tao; Zhi-Fu ; et al.	2018-12-13
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Grant 10,081,628 - Tao , et al. September 25, 2	2018-09-25
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20180221363 - WANG; Le ; et al.	2018-08-09
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20180140595 - Wang; Le ; et al.	2018-05-24
Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases Grant 9,877,958 - Wang , et al. January 30, 2	2018-01-30
Methods of treatment using selective Bcl-2 inhibitors Grant 9,872,861 - Elmore , et al. January 23, 2	2018-01-23
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Grant 9,844,547 - Wang , et al. December 19, 2	2017-12-19
Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors Grant 9,796,708 - Tong , et al. October 24, 2	2017-10-24
Methods Of Treatment Using Selective Bcl-2 Inhibitors App 20170232000 - Elmore; Steven ; et al.	2017-08-17
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20170008891 - Tao; Zhi-Fu ; et al.	2017-01-12
Methods Of Treatment Using Selective Bcl-2 Inhibitors App 20160235760 - Elmore; Steven ; et al.	2016-08-18
Apoptosis-induced Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20160206611 - Wang; Le ; et al.	2016-07-21
Methods of treatment using selective Bcl-2 inhibitors Grant 9,345,702 - Elmore , et al. May 24, 2	2016-05-24
Tetracyclic CDK9 kinase inhibitors Grant 9,328,112 - Frey , et al. May 3, 2	2016-05-03
Pyrrolo [2,3-b] Pyridine Cdk9 Kinase Inhibitors App 20160060257 - Tong; Yunsong ; et al.	2016-03-03
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Grant 9,266,877 - Wang , et al. February 23, 2	2016-02-23
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20150299197 - Tao; Zhi-Fu ; et al.	2015-10-22
Tetracyclic Cdk9 Kinase Inhibitors App 20150218165 - Frey; Robin ; et al.	2015-08-06
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20150152097 - Wang; Le ; et al.	2015-06-04
Methods Of Treatment Using Selective Bcl-2 Inhibitors App 20150150870 - Elmore; Steven ; et al.	2015-06-04
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Grant 8,940,737 - Wang , et al. January 27, 2	2015-01-27
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Grant 8,889,675 - Wang , et al. November 18, 2	2014-11-18
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20140275082 - Tao; Zhi-Fu ; et al.	2014-09-18
Apoptosis-induced Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20130096120 - WANG; LE ; et al.	2013-04-18
Apoptosis-inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases App 20130096121 - Wang; Le ; et al.	2013-04-18
Methods Of Treatment Using Selective Bcl-2 Inhibitors App 20120129853 - Elmore; Steven ; et al.	2012-05-24
Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme App 20080064717 - Iyengar; Rajesh ; et al.	2008-03-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.